Advanced Tissue Sciences Inc.: learning from the past, a case study for regenerative medicine
Abstract
On 31st March 2003 Advanced Tissue Sciences (ATS) was liquidated, with the effect that in excess of US$300 million of stakeholder financing was destroyed. Although successful in the development of breakthrough technologies in the regenerative medicine arena and the building of a substantial portfolio of patents, the company never made a profit. In this case study, ATS’ business strategy, market and competitive environment will be discussed in the context of the company’s historical development. A number of important lessons from this case are discussed. From a management perspective the most critical lesson is the importance of effective financial planning and management of costs, and in particular R&D costs, including the significant costs associated with clinical trials. In addition, a clear strategic focus is extremely important due to the significant resources required in the development of a new therapy. From an investor’s perspective the lessons to be gathered from the ATS case are related to the risk involved in investing in the field of regenerative medicine. This case indicates that both professional and private investors did not fully question the validity of ATS’ business strategy and financial forecasts. A clear and focused strategy based on long-term investor commitment is essential for the successful commercialization of regenerative medicine.
Bibliography
- 1 Webb M: Trade group honors local bioengineering pioneer. San Diego Business Journal21(27),6 (2000).
- 2 Diekman JM: Skin replacement opens million dollar markets. Health Industry Today5(7),7–8 (1992).
- 3 Pitta J: Biosynthetics. Forbes151(10),170–171 (1993).
- 4 Brennan T: Advanced Tissue Sciences sale OK’d. The Daily Deal, 20th March (2003).
- 5 Turner R: California concern is encouraged by tests of ‘living skin’ process. Wall Street Journal, 19th October, A9A (1992).
- 6 Advanced Tissue Sciences Inc.: FDA approves the product for treating burn patients. Wall Street Journal, 19th March, B4 (1997).
- 7 Webb M: Tissue engineers see brave new world ahead. San Diego Business Journal19(38),1 (1998).
- 8 Fikes BJ: Marrow tech changes it’s name, launches second public offering. San Diego Business Journal13(1),12 (1992).
- 9 Advanced tissue sets skin-product venture with Smith and Nephew. Wall Street Journal, 30th April B8 (1996).
- 10 Fikes BJ: Man-made liver at heart of firm’s future. San Diego Business Journal15(2),1 (1994)
- 11 Sowing cells, growing organs. The Economist338(7947),65–66 (1996).
- 12 Fikes BJ: Advanced Tissue gains market as main rival exits with skin test. San Diego Business Journal14(6),6 (1993).
- 13 Rundle RL, Womack A: Skin product wins support of FDA panel.Wall Street Journal, 20th November, B10 (1996).
- 14 Kravetz S: Advanced Tissue’s Shares plummet 44% in wake of ulcer-treatment decision. Wall Street Journal, 15th June, 1 (1998).
- 15 Arnst C: The latest from the labs: human skin; the FDA is about to approve commercial use of living tissue grown by two biotech outfits. Business Week, 18th May, 118 (1998).
- 16 FDA is seeking more data on foot-ulcer treatment. Wall Street Journal, 12th June, 1 (1998).
- 17 Webb M: ATS forms anti-aging market unit. San Diego Business Journal23(13),1 (2002).
- 18 Webb M: Doctors impressed with ATS product Dermagraft®. San Diego Business Journal22(41),9 (2001).
- 19 Hower W: Maker of human tissue finds california partner. The Boston Business Journal12(18),7 (1992).
- 20 St. Jude Medical Inc.: Wall Street Journal, 15th February, B2 (1994).
- 21 Silverman SD, Cinguina JA: A joint effort; building blocks. International Business7(8),68–70 (1994).
- 22 NIH grant is received to develop jaw cartilage. Wall Street Journal, 15th September, C14 (2000).
- 23 Rundle RL: Biotech firms turn to cosmetic-surgery market. Wall Street Journal (Eastern Edition), 12th May, 1 (1999).
- 24 Crabtree P: La Jolla, Calif.-based biotech firm files for chapter 11 bankruptcy protection. Knight Ridder Tribune Business News, 11th October, 1 (2002).
- 25 Morse A: Advanced tissue sciences files Ch. 11. The Daily Deal, 11th October (2002).
- 26 Shares plunge after La Jolla, Calif.-based biotech firm files for bankruptcy. Knight Ridder Tribune Business News, 12th October, 1 (2002).
- 27 Rose CD: California-based biotechnology firm to fold. Knight Ridder Tribune Business News, 14th November (2002).
- 28 Champ S: MBA thesis: evolution of the regenerative medicine industry and the influence of alliances on organisational performance. Warwick Business School, Coventry, UK.
- 101 Shaw G: An industry’s springtime. From the Publisher, San Diego Metropolitan Magazine http://sandiegometro.archives.whsites.net/1997/apr/publisher.html
- 102 Advanced Tissue Science Liquidating Trust, Final Cash Basis Financial Statements www.advancedtissue.com (Accessed 31st March 2009)
- 103 Bonfiglio GA: Funding and exit strategies for regenerative medicine companies (2006) www.proteusvp.com/Marcus%20Evans%20Conference%20Presentation.pdf
